former CSO
Selecta Biosciences
Lexington, Massachusetts, United States
Dr. Kishimoto is an independent consultant and former Chief Scientific Officer of Selecta Biosciences, a biotechnology company that developed tolerogenic ImmTOR technology to mitigate unwanted immune responses, which successfully completed Phase 3 clinical trials. Prior to joining Selecta, Dr. Kishimoto held leadership positions of increasing responsibility at Momenta Pharmaceuticals, Millennium Pharmaceuticals, and Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.
Disclosure information not submitted.
Wednesday, June 19, 2024
1:40 PM – 2:05 PM PT
